Despite being the second most prevalent mental disorder with a third of the general population reporting insomnia complaints and 10 percent meeting the strict definition of insomnia disorder, the treatment options for the disease are lacking. Considering that many treatments lead to tolerance and dependence and the potential for morning sedation, drugs using new mechanisms of action are sorely needed.
After a drought of nearly a decade without an FDA approval, the market for hepatocellular carcinoma (HCC), the most common type of primary liver cancer in adults, is heating up.
Oral mucositis, painful sores that form in the mouths of many cancer patients, are more than just an annoying side effect of radiation and chemotherapy treatments. When they reach grade 3, patients can no longer eat solid foods, and at grade 4 patients can no longer even drink, often resulting in the stopping of cancer treatments.
In what seems to be an eternally growing partnership, Regeneron Pharmaceuticals Inc. and Sanofi SA plan to accelerate development of two drugs already partnered under their multidrug agreements.
Roche Holding AG is acquiring San Diego-based Ignyta Inc. for $1.7 billion with an offer of $27 per share in cash, a 74 percent increase over its closing price on Thursday.
Christmas came early for Aerie Pharmaceuticals Inc. with an FDA approval of Rhopressa (netarsudil) for open-angle glaucoma or ocular hypertension on Monday – or maybe call it an early Valentine's Day gift considering the PDUFA goal date wasn't until Feb. 28, 2018.
Many companies have tried and failed to make an HIV vaccine capable of preventing HIV infection, but the virus has eluded more than 30 vaccines so far.
Many companies have tried and failed to make an HIV vaccine capable of preventing HIV infection, but the virus has eluded more than 30 vaccines so far.
Immuno-oncology drugs Keytruda (pembrolizumab, Merck & Co. Inc.) and Opdivo (nivolumab, Bristol-Myers Squibb Co.) came in first and third in the latest edition of the Trinity Drug Index, with hepatitis C drug Harvoni (sofosbuvir/ledipasvir, Gilead Sciences Inc.) taking the second spot. This version of the annual index scores the 41 drugs approved by the FDA in 2014 based on commercial, therapeutic and R&D categories.